BIO-Europe® 2014 international partnering conference will take place, November 3–5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
The conference will kick off with keynote addresses by Andreas Busch, Member, Executive Committee;, Head, Global Drug Discovery, Bayer HealthCare; David Loew, Senior VP, Commercial Operations, Europe, Sanofi; and Luciano Rossetti, Executive VP, Head of Global Research and Development, Member of the Pharmaceutical Executive Committee, Merck Serono. The keynote will be followed by their participation in an Opening Plenary Discussion entitled “Biopharma strategy: More focus, more value?” moderated by Jean-François Formela, Partner, Atlas Venture.
A keynote plenary discussion entitled “A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014” will headline the second day of the conference. The keynote plenary will be moderated by Evonne Sepsis, Founder and Managing Director at ESC Advisors and David Stubbs, Founding Partner and Managing Director at Inverness Advisors. The featured panelists are Iain Dukes, Senior VP, Business Development and Licensing at Merck; Shaun Grady, VP, Business Development Operations, AstraZeneca; Adam Keeney, Global Head, External Innovation Operations Strategy, Science Policy and External Innovation, Sanofi; and James Sabry, Senior VP, Global Head of Partnering, Genentech.
“The most compelling aspect of the BIO-Europe keynote plenary topic is sharing reflections on various transformational deals taking place across the industry and unpacking what makes them game-changers,” said Grady. “We’ll discuss what makes a deal within our industry truly transformational, highlighting innovation in the deal structure and the linkage with R&D strategy, assessing commercial potential, and securing and incentivizing the commitment of partners involved. The magic is very often in the details.”
“In thinking about deals at Sanofi, we focus on the opportunities that have the ability to deliver transformational solutions that can significantly benefit the patient,” said Keeney. “Because in the end, deals that transformed the market were those that were open to a paradigm shift in their thinking about disease, and in the way they structured their R&D to remain innovative. I think this bears on our discussion at BIO-Europe.”
Other highlights of the BIO-Europe program include dual track Parallel Panel Discussions. In the Business Development Track, topics range from access to medicines in late-stage clinical trials to funding for EU companies, early market access and sell-side dealmakers. The Spotlight Track features topics ranging from late stage complications in diabetes and next-generation cancer therapies and immunotherapies, to corporate views on personalized immune intervention and advancements in orphan drugs.
In addition, the afternoon will feature Pharmaceutical company presentations from the many pharma companies confirmed to send business development teams to BIO-Europe 2014. They include AbbVie; Alexion Pharmaceuticals; Amgen; AstraZeneca; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Licensing; Bristol-Myers Squibb; Daiichi Sankyo Co., Ltd.; Eli Lilly and Company; Genentech; GlaxoSmithKline; Janssen Pharmaceutical Companies of Johnson & Johnson; Merck Serono; MSD; Novartis; Novo Nordisk; Pfizer; Roche; Sanofi; and Takeda.
At BIO-Europe, companies participate in one-to-one partnering meetings facilitated by EBD Group’s highly reputable partneringONE® platform.
The 2013 edition featured 17,874 one-to-one partnering meetings, an all-time record. Over 3,200 delegates from 1,841 companies representing 56 countries attended. There were 184 company presentations with close to 3,600 licensing opportunities on offer, and 95 exhibitors at the event.
Registration information is available on the BIO-Europe web site for Europe’s largest partnering conference serving the global biotechnology industry.
About BIO-Europe® 2014:
The 20th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry.
Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
Follow BIO-Europe 2014 on Twitter: twitter.com/ebdgroup (hashtag: #BEU14). Or log on to the Life Science Partnering discussion forum on partnering360. The Group is your go-to discussion forum for news and topics related to BIO-Europe.
About EBD Group EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year. EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world. EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
+1 760 930 0500